# Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

> **NCT05093855** · PHASE2 · COMPLETED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 41 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** BDB-001 Injection

## Key facts

- **NCT ID:** NCT05093855
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-18
- **Primary completion:** 2023-08-22
- **Final completion:** 2023-08-22
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093855, "Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05093855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*